Effect of polychemotherapy in the treatment of patients with non-Hodgkin's lymphoma
Belić, A.; Popović, S.; Savić, I.
Medicinski Pregled 45(5-6): 188-193
1992
ISSN/ISBN: 0025-8105 PMID: 1365055 Document Number: 394713
Non-Hodgkin lymphomas belong to malignant hemopathies where clinical course, histological manifestation and therapy response are characterized by diverse features. Sensitivity of the lymphoma to chemotherapy introduced drug combinations for the improvement of patient survival rate and the prognosis. The study reviews the results achieved in 85 patients with NHL treated with different cytostatic combinations (COP, CHOP, COP-BLAM, MEV, LRS-074/B). The majority of the patients (41%) had entered the IV clinical stadium (Ann Arbor) with serious histological types of the disease (LDLL-45% and histiocytic 27%). This made us decide on LRS-074/B protocol (34%) and COP-BLAM cure (20%) planned for those with the advanced clinical stage and poor histological type of the disease. The full remission was achieved in 50%, partial in 28% of the cases while in 20% of the treated patients the therapy response lacked. Relapse of the disease occurs in about 50% of the treated patients. Patients treated with LRS-074/B protocol (p < 0.05) live statistically significantly longer. In a period of 24 months 50% of those treated with LRS-074/B protocol, COP and COP-BLAM cures show no symptoms. There is no a statistically significant difference regarding the mean survival rate (p > 0.05) in relation to the histological type of the disease.